Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 4:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 9,649 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Human Clear all
Recruiting Phase 2 Interventional

Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma

NCT07731789
View directory record Official record
Conditions
Classic Follicular Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma
Interventions
Rituximab, Tafasitamab, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Positron Emission Tomography, Survey Administration
Biological · Procedure · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 25, 2026, 4:04 PM EDT
Terminated Phase 1 Interventional

Safety Study of TXA127 to Elevate CD4+ T-Lymphocyte Counts in HIV-Infected Patients on Stable HAART Therapy

NCT00757250
View directory record Official record
Conditions
HIV Infections
Interventions
Angiotensin 1-7
Drug
Lead sponsor
US Biotest, Inc.
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
3
States / cities
Los Angeles, California • San Diego, California • Torrance, California
Source: ClinicalTrials.gov public record
Updated Feb 29, 2012 · Synced Oct 25, 2026, 4:04 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Recombinant Human Insulin-Like Growth Factor (rhIGF-1) Treatment of Short Stature Associated With IGF-1 Deficiency

NCT00125190
View directory record Official record
Conditions
Insulin-Like Growth Factor-1 Deficiency, Growth Disorders
Interventions
rhIGF-1 (mecasermin) for a period of 86 weeks
Drug
Lead sponsor
Ipsen
Industry
Eligibility
3 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Brisbane, California
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Oct 25, 2026, 4:04 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer

NCT00019110
View directory record Official record
Conditions
Anal Cancer, Cervical Cancer, Esophageal Cancer, Head and Neck Cancer, Penile Cancer, Vulvar Cancer
Interventions
human papillomavirus 16 E7 peptide, synthetic human papillomavirus 16 E6 peptide
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1995
U.S. locations
6
States / cities
Bethesda, Maryland • Boston, Massachusetts • Morristown, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2015 · Synced Oct 25, 2026, 4:04 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

A Comparison of IV Versus PO Acetaminophen Postoperatively for Opioid Consumption After Cesarean Section

NCT04290208
View directory record Official record
Conditions
Postoperative Pain, Cesarean Section, Acetaminophen
Interventions
Acetaminophen, Placebos
Drug
Lead sponsor
Main Line Health
Other
Eligibility
18 Years and older · Female only
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Wynnewood, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 28, 2020 · Synced Oct 25, 2026, 4:04 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effects of GLA (5 mcg) on Human Volunteers

NCT01864876
View directory record Official record
Conditions
Healthy Volunteers
Interventions
GLA-AF, GLA-SE, EM060G (SE)
Biological
Lead sponsor
Access to Advanced Health Institute (AAHI)
Other
Eligibility
18 Years to 50 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 26, 2014 · Synced Oct 25, 2026, 4:04 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of DM005 in Patients With Advanced Solid Tumors

NCT06515990
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of Head and Neck, Solid Carcinoma
Interventions
DM005
Drug
Lead sponsor
Doma Biopharmaceutical（Suzhou）Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Detroit, Michigan • Dallas, Texas • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 25, 2026, 4:04 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Role of Nitric Oxide in the Impact of Aging on Myocardial Remodeling

NCT00603720
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
L-NAME, L-Arginine, Phenylephrine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 12, 2018 · Synced Oct 25, 2026, 4:04 PM EDT
Terminated Phase 2 Interventional Results available

9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic Adenocarcinoma

NCT05239182
View directory record Official record
Conditions
Pancreatic Adenocarcinoma
Interventions
9-ING-41, Retifanlimab, Gemcitabine, Abraxane
Drug
Lead sponsor
Anwaar Saeed
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Fairway, Kansas • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Oct 25, 2026, 4:04 PM EDT
Withdrawn Not applicable Interventional

Secretin-enhanced Magnetic Resonance Cholangiopancreatography (S-MRCP) and Pancreatic Function Following Surgery

NCT01094535
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Synthetic Human Secretin
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Oct 25, 2026, 4:04 PM EDT
Recruiting Not applicable Interventional

Olfactory Biopsies

NCT07021040
View directory record Official record
Conditions
Alzheimer Disease, Smell Loss, Smell Dysfunction
Interventions
olfactory testing, Odor stimulation, Olfactory biopsy
Diagnostic Test · Other · Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 25, 2026, 4:04 PM EDT
Completed No phase listed Observational

Natural Cycle In Vitro Fertilization

NCT01866618
View directory record Official record
Conditions
Natural Cycle in Vitro Fertilization (IVF)
Interventions
Not listed
Lead sponsor
Reproductive Medicine Associates of New Jersey
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
524 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Basking Ridge, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 9, 2018 · Synced Oct 25, 2026, 4:04 PM EDT
Recruiting Phase 3 Interventional

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

NCT06337318
View directory record Official record
Conditions
Classic Follicular Lymphoma, Follicular Lymphoma With Unusual Cytological Features
Interventions
Biospecimen Collection, Computed Tomography, Mosunetuzumab, Positron Emission Tomography, Rituximab, Rituximab and Hyaluronidase Human
Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
287
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 229 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 25, 2026, 4:04 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans: Sub-Study I

NCT02811510
View directory record Official record
Conditions
Cannabis
Interventions
Placebo, Dronabinol
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2026
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced Oct 25, 2026, 4:04 PM EDT
Recruiting Phase 2 Interventional

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

NCT06797635
View directory record Official record
Conditions
Breast Neoplasms, Breast Cancer
Interventions
Patritumab deruxtecan, Pembrolizumab, Paclitaxel, Carboplatin, Doxorubicin hydrochloride, Epirubicin hydrochloride, Cyclophosphamide, Capecitabine, Olaparib
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
372 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
8
States / cities
Santa Monica, California • Skokie, Illinois • Billings, Montana + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 25, 2026, 4:04 PM EDT
Completed Phase 4 Interventional Results available

Menopur® Versus Follistim® in Polycystic Ovarian Syndrome (PCOS)

NCT00805935
View directory record Official record
Conditions
Polycystic Ovarian Syndrome, Infertility
Interventions
Menotropin, Progesterone vaginal insert, Follitropin beta, Progesterone in oil, leuprolide acetate
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years to 42 Years · Female only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
6
States / cities
Littleton, Colorado • Clearwater, Florida • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2012 · Synced Oct 25, 2026, 4:04 PM EDT
Withdrawn Phase 4 Interventional

Topical Corticosteroid Use in Addition to Oral Antivirals for Prevention of Recurrence of Herpes Simplex Virus (HSV) Keratitis

NCT03626376
View directory record Official record
Conditions
Herpes Simplex Virus Keratitis
Interventions
oral acyclovir 400 mg BID OR valacyclovir 500 mg qdaily, oral acyclovir 400 mg BID OR valacyclovir 500 mg qdaily + topical corticosteroid eye drops
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 14, 2022 · Synced Oct 25, 2026, 4:04 PM EDT
Completed No phase listed Observational

Developing a New Metabolic Imaging Approach (aMRI) for Evaluating Neurological Disease in Patients With Gliomas

NCT05937776
View directory record Official record
Conditions
Glioma
Interventions
Fludeoxyglucose F-18, Gadoterate Meglumine, Contrast-enhanced Magnetic Resonance Imaging, Positron Emission Tomography
Other · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 25, 2026, 4:04 PM EDT
Completed Phase 1 Interventional Results available

Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant

NCT00513474
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
busulfan, cyclophosphamide, cyclosporin-A, etoposide, methotrexate, rasburicase, sirolimus, tacrolimus, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, total-body irradiation, fludarabine, allopurinol
Drug · Procedure · Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 25, 2017 · Synced Oct 25, 2026, 4:04 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Exercise Detection Study

NCT02688218
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Aerobic Exercise, Resistance Exercise
Behavioral
Lead sponsor
Oregon Health and Science University
Other
Eligibility
21 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 29, 2019 · Synced Oct 25, 2026, 4:04 PM EDT
Completed Phase 2Phase 3 Interventional

Efficacy and Safety Study of Protein C Concentrate in Subjects With Severe Congenital Protein C Deficiency

NCT00157118
View directory record Official record
Conditions
Protein C Deficiency
Interventions
Protein C Concentrate (Human) Vapor Heated
Drug
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
Not listed
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
12
States / cities
Los Angeles, California • Denver, Colorado • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated May 5, 2021 · Synced Oct 25, 2026, 4:04 PM EDT
Enrolling by invitation Not applicable Interventional

Human Thalamus in Propagation of Temporal Lobe Seizures and Memory Formation

NCT07226908
View directory record Official record
Conditions
Epilepsy
Interventions
Cognitive experiment, Electrical stimulation of the brain
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 25, 2026, 4:04 PM EDT
Terminated Phase 1 Interventional

Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant

NCT02846376
View directory record Official record
Conditions
Acute Myeloid Leukemia and Myelodysplastic Syndrome
Interventions
Nivolumab, Ipilimumab
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years to 70 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 18, 2024 · Synced Oct 25, 2026, 4:04 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Role of Prostaglandins in the Regulation of Brain Blood Flow

NCT00006318
View directory record Official record
Conditions
Healthy, Hypercapnia
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 25, 2026, 4:04 PM EDT